Literature DB >> 33508793

Standardization of the Korean Version of the Patient Health Questionnaire-4 (PHQ-4).

Hyoun-Wook Kim1, Cheolmin Shin2, Seung-Hoon Lee3, Changsu Han2.   

Abstract

OBJECTIVE: The Patient Health Questionnaire-4 (PHQ-4) has been used for screening owing to ease of use and brevity. In this study, we developed the Korean version of the PHQ-4 and tested its validity.
METHODS: One hundred sixteen new adult outpatients at the Department of Psychiatry of the Korea University Ansan Hospital participated in the study. We simultaneously administered other depression/anxiety scales: the Hamilton Rating Scale for Depression, the Hamilton Anxiety Scale, the Beck Depression Inventory, and the Beck Anxiety Inventory.
RESULTS: The mean PHQ-4 score was 6.52 (standard deviation = 3.45). Cronbach's α was 0.792, and the intraclass correlation coefficient of test and 2-week interval retest was 0.827 (p < 0.01). The Pearson correlation coefficients between the PHQ-4 total score and other depression/anxiety scales were all over 0.6. Confirmatory factorial analysis showed acceptable convergent validity and reliability but questionable discriminant validity for some model fit values.
CONCLUSION: The Korean version of the PHQ-4 has sufficient internal consistency, test-retest reliability, and construct validity, but its two-factor structure showed incompleteness. However, we suggest that it should be used as a brief screening measure for common psychiatric distress that warrants further detailed assessment, but not to separately assess the severity of depression and anxiety symptoms.

Entities:  

Keywords:  Anxiety; Depression; Patient Health Questionnaire-4; Screening; Standardization

Year:  2021        PMID: 33508793      PMCID: PMC7851451          DOI: 10.9758/cpn.2021.19.1.104

Source DB:  PubMed          Journal:  Clin Psychopharmacol Neurosci        ISSN: 1738-1088            Impact factor:   2.582


INTRODUCTION

Depressive disorders are among the most common psychiatric disorders and a major cause of disability [1]. These disorders account for 3.0% (2.2−3.8%) of global Disability-Adjusted Life Years (DALY), contributing to 16 million suicidal DALYs and 4 million ischemic heart disease DALYs per year [2]. In the United States, the economic cost of major depressive disorders rose by 21.5% over five years to $210.5 billion in 2010. In Korea, the prevalence rate of major depression disorders has risen to 3.6% [3]. Anxiety disorders are also among the most common psychiatric disorders, with a global prevalence rate of 28.8% [4], and a 9.1% rate in Korea specifically [3]. In the United States, the economic cost of anxiety disorders totals $42.3 billion [5]. However, many patients afflicted with these diseases do not receive proper treatment. Only 2.2% of patients with symptoms of depression visit a doctor, and only 7.4% of them receive antidepressants [3]. A study of clinical practice guidelines for depression and the education of primary physicians showed that trained doctors were able to identify 39% of depressed patients [6]. Another study showed that 41% of patients with anxiety disorders were not receiving treatment [7]. One reason for this lack of treatment is time constraints; 90% of primary physicians said that more time is needed to diagnose depression compared to other diseases [8]. There are some measures used in the screening of depressive and anxiety disorders. The Patient Health Questionnaire (PHQ-9) measures the severity of depression. Each of the nine questions evaluates the symptoms of the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV), the diagnostic standard for major depressive disorders [9]. The PHQ-2 is derived from the PHQ-9 and measures only two key symptoms of the diagnostic standard: depression and decreased interest. This reduces the time and effort required for the examination, which makes it suitable for screening [10]. The Generalized Anxiety Disorder Scale-7 (GAD-7) is a questionnaire that measures the severity of generalized anxiety disorders [11]. The GAD-2 consists of two core items from the GAD-7, and is also suitable for screening purposes, as it shows good sensitivity in diagnosing not only generalized anxiety disorders, but also panic disorder, social anxiety disorder, and post-traumatic stress disorder [7]. PHQ-4 combines the items from the PHQ-2 and GAD-2 [12]; therefore, it is a brief screening tool for assessing the key symptoms of depression and anxiety. As mentioned above, depressive and anxiety disorders show high prevalence rates and frequent comorbidity [13,14]. The degree of the resultant disability increases further in cases of comorbidity [15 -17] and thus, the PHQ-4 is a useful tool for screening both disorders. The article that developed the PHQ-4 confirmed the construct and factor validities and the total scores were found to be related to the degree of functional disability [12]. In another study, the PHQ-4’s validity in the general population was confirmed and normative data was obtained [18]. Due to cultural differences, the validity of screening questionnaires can be negatively impacted when translated into other languages. Therefore, it is necessary to develop a Korean version of the PHQ-4 and to verify its validity and reliability. If the Korean version of the PHQ-4 is developed through this study, it could be used as a brief and simple screening tool for depressive and anxiety disorders in a wide range of clinical environments, including psychiatry, primary care, and secondary/tertiary medical institutions. This further promotes public mental health practices.

METHODS

Study Design and Participants

The study was conducted between August 2017 and December 2018. The participants were new outpatients at the Department of Psychiatry of Korea University Ansan Hospital, aged 19 years or older. The study excluded patients whose cognitive abilities had deteriorated to such a degree that they would have had difficulty understanding and completing the research consent forms and questionnaires, or participating in interviews. The target sample size was determined to be 112; this assumed a 10% dropout rate, with an α level of 0.05 and power of 0.8, in accordance with the Cronbach’s α figure derived from existing standardization studies [18,19]. Following the completion of a self-report questionnaire and an observer scale, the participants were examined and then retested two weeks later. One psychiatric resident doctor (HW Kim) completed all observer scales. All participants signed an informed consent form and all research processes were conducted under the approval of the institutional review board (IRB) of the Korea University Ansan Hospital (IRB no. 2017AS0051).

Measures

Korean version of the PHQ-4

The Korean version of the PHQ-4 consists of the first two items of the Korean version of the PHQ-9 [20] and the first two items of the Korean version of the GAD-7. The items measure core symptoms of major depressive disorder and generalized anxiety disorder; items from the PHQ-9 ask about depression and anxiety, items from the GAD-7 ask about nervous feelings and uncontrollable worrying. All items are scored from 0 to 3 depending on the frequency patients have been bothered by the symptoms over the preceding two weeks. Our research team developed the Korean version of the GAD-7 through a consecutive process of translation and retranslation, until clinical psychiatrists confirmed that the translation fully reflected the meaning of the original GAD-7 and was suitable for Koreans. A paper concerning this development and the validation of the Korean version of the GAD-7 will be published soon.

Korean version of the Hamilton Rating Scale for Depression

The Hamilton Rating Scale for Depression (HAM-D) is considered the gold-standard for observer-rating scales for depression [21] and was initially composed of 21 items. However, the last four items were deemed to be less informative and lacked internal consistency, so the 17-item version is now widely used [22]. The HAM-D is a semi-structured interview scale in which the observer evaluates the following: nine items (depressive mood, guilty feeling, suicidal ideation, work and activity, psychomotor retardation or agitation, mental anxiety, physical anxiety, and hypochondriasis) which are graded from 0 to 4 points; seven items (early, mid-term, late insomnia, gastrointestinal somatic symptoms, general somatic sym-ptoms, sexual symptoms, and insight) which are graded from 0 to 2 points; and one item for weight loss graded from 0 to 3 points. The reliability and validity of the Korean version of the HAM-D has been demonstrated [23].

Korean version of the Hamilton Anxiety Rating Scale

The Hamilton Anxiety Scale (HAM-A) is an clinician-rating scale consisting of 14 questions that measures the severity of anxiety symptoms, with a total score that ranges from 0 to 56 [24]. The HAM-A measures both general psychic anxiety (agitation and psychological distress) and somatic anxiety (anxiety-related physical complaints).

Korean version of the Beck Depression Inventory

The Beck Depression Inventory (BDI) is a self-reporting measure developed to assess depressive symptoms and their severity [25]. The BDI-II was then developed to meet the diagnostic criteria of the DSM-IV [26]. It has 21 questions with a total score that ranges from 0 to 63. The validity of the Korean version of the BDI-II has been demonstrated [27].

Korean version of the Beck Anxiety Inventory

The Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire widely used as a simple and highly relevant measure that assesses anxiety symptoms and their severity [28]. The Korean version of the BAI was translated by Kwon and Oei [29].

Korean version of the Mini-International Neuropsychiatric Interview

The Mini-International Neuropsychological Interview (MINI) is a structured interview that diagnoses psychiatric disorders based on the DSM-IV and the International Classification of Diseases version 10. Minimal training is required to administer this simple, brief, and effective (15 minute) interview [30]. The validity of the Korean version of the MINI has been demonstrated [31].

Data Analysis

In this study, Cronbach’s α was used to analyze the internal consistency of the Korean version of the PHQ-4. In addition, the intraclass correlation coefficient was obtained from the tests conducted at the two-week interval to explore the test-retest reliability. To determine construct validity, we obtained the correlation between the total PHQ-4 score and each score from the following scale measures: HAM-D, HAM-A, BDI, and BAI. The correlation between the PHQ-4 depression/ anxiety subtotal score and the above scale measures was also obtained. Factorial validity was examined using exploratory factor analysis and confirmatory factor analysis. For confirmatory factor analysis, we constructed a structural equation model (SEM) that holds two factors, depression and anxiety, which was regressed from first two items and last two items of the PHQ-4. The convergent validity and reliability of the model was examined through composite validity (CR) and the average variance extracted (AVE). The CR should be greater than 0.7, and the AVE should be greater than 0.5 [32]. Discriminant validity was also examined by confirming whether the maximum shared variance (MSV) was less than the AVE. The model fit was evaluated using a normed chi-square (CMIN/df), the root mean square error of approximation (RMSEA), the standardized root mean square residual (SRMR), the Tucker−Lewis index (TLI), and the comparative-fit-index (CFI). The respective threshold of each measurement is as follows: < 3, < 0.05, < 0.09, > 0.95, and > 0.95 [33]. All statistical analyses were conducted using IBM SPSS Statistical Package for the Social Sciences ver. 23.0 (IBM Co., Armonk, NY, USA) and IBM SPSS Amos ver. 23.0 (IBM Co., Armonk, NY, USA).

RESULTS

Sample characteristics

One hundred sixteen individuals participated in the study. The mean of the PHQ-4 total scores was 6.52 with a standard deviation (SD) of 3.45. The sociodemographic characteristics of the sample are described in Table 1. ANOVA analysis of the PHQ-4 scores showed significant differences in those aged 51 or above compared to other age groups, in those who were divorced or separated relative to other marital statuses, and in the low income group relative to those with other income levels.
Table 1

Sociodemographic characteristics and PHQ-4 scores of the study sample

CharacteristicNumber%PHQ-4 score p value

MeanSD
SexMale6556.06.803.7250.336
Female5144.06.163.064
Age group19−306556.07.333.3710.014*
31−401311.26.312.926
41−501512.96.293.496
51−601613.84.873.357
Over 6176.03.573.047
Marital statusMarried3631.05.003.6180.004*
Divorced/separated76.07.861.864
Unmarried7060.37.263.257
Widowed32.63.672.082
Employment statusEmployed4841.46.193.5180.393
Unemployed6858.66.763.415
RegionMetropolitan97.85.563.7790.422
Suburban10691.46.573.432
Rural10.910.00-
ReligionNone8371.66.743.2550.257
Christian1714.76.183.762
Catholic32.62.001.414
Buddhist108.66.204.237
Economic statusHigh----< 0.01*
Moderate-high4841.45.283.308
Moderate-low4337.16.493.203
Low2319.88.832.980

PHQ-4, The Patient Health Questionnaire-4; SD, standard deviation.

*p < 0.05.

The psychiatric diagnoses of the study sample are described in Table 2. Those who were diagnosed with two or more disorders were assigned to both categories. The sample sizes were too small for categorization into specific disorders except major depressive disorder, panic disorder, and adjustment disorder. In general, the depression subtotal score (PHQ-2 score) relative to the anxiety subtotal score (GAD-2) score tended to be higher in anxiety disorders, and vice versa.
Table 2

Psychiatric diagnosis and total/subtotal PHQ-4 score of the study sample

Psychiatric diagnosisNumber%PHQ-4PHQ-2GAD-2



MeanSDMeanSDMeanSD
Major depressive disorder6757.87.043.123.751.823.301.84
Bipolar disorder21.78.500.715.000.003.001.00
Dysthymia21.79.004.245.001.414.002.83
Generalized anxiety disorder21.74.500.712.330.582.500.71
Panic disorder3227.66.913.703.392.183.422.00
Social/specific phobia43.45.502.382.501.733.000.82
Obsessive-Compulsive disorder21.78.500.712.500.716.000.00
Somatization disorder10.99.000.003.000.006.000.00
Adjustment disorder1512.96.074.483.472.202.602.50
Alcohol dependence21.77.007.074.002.833.004.24
Psychotic disorder32.64.001.002.000.002.001.00

PHQ-4, The Patient Health Questionnaire-4; PHQ-2, The Patient Health Questionnaire-2; GAD-2, The Generalized Anxiety Disorder Scale-2; SD, standard deviation.

Reliability

The Cronbach’s α value for the Korean version of the PHQ-4 was measured at 0.792, which suggests acceptable internal consistency [34]. As described in Table 3, all items showed significant associations with the total PHQ-4 score. When each item was removed, the Cronbach’s α value did not increase.
Table 3

Corrected item-total correlations and Cronbach’s α if an item is deleted

ItemCorrected item-total correlationCronbach’s α if an item deleted
10.5430.772
20.6430.721
30.6310.729
40.6010.742
The intraclass correlation coefficient for test-retest values was excellent at 0.827, with a p value less than 0.01 [35]. The average of the first PHQ-4 scores was 6.54 with a SD of 3.44; whereas the average of the second PHQ-4 scores was 5.50 with a SD of 3.94.

Construct validity

The correlation analysis to measure structural validity is described in Table 4. It was observed that all scores and subscales of the PHQ-4 were sufficiently correlated with BDI, BAI, HAM-D, HAM-A, and had a Pearson correlation coefficient of 0.5 or more. However, the total PHQ-4 score showed a higher correlation to BDI and HAM-D than the PHQ-4 depression subscale, and was also higher than the correlation between the PHQ-4 anxiety subscale and the BAI and HAM-A.
Table 4

Correlation between PHQ-4 and concurrent validity measures

ScalePHQ-4 total scoreDepression scoreAnxiety score
BDI0.762** 0.656** 0.678**
HAM-D_170.720** 0.654** 0.615**
BAI0.728** 0.567** 0.716**
HAM-A0.680** 0.548** 0.647**

PHQ-4, The Patient Health Questionnaire-4; BDI, The Beck De-pression Inventory; HAM-D, The Hamilton Rating Scale for De-pression; BAI, The Beck Anxiety Inventory; HAM-A, The Hamilton Anxiety Scale.

**p < 0.01.

Factorial validity

The exploratory factor analysis demonstrated a 1-factor structure of the PHQ-4. The factor loadings for items 1 to 4 were 0.81, 0.80, 0.79, and 0.74, respectively. In Figure 1A, the SEM for confirmatory factor analysis includes two factors, depression and anxiety, the standardized regression weights for each questionnaire item, and the covariance between them. Standardized regression weights were all above 0.5, which means that the two factors show sufficient explanatory power for each item. However, the covariance between the depression and anxiety factors was also high, suggesting that these two factors are not sufficiently independent. The AVE and CR for depression were 0.566 and 0.721, and 0.605 and 0.754 for anxiety, these all sufficiently indicate convergent validity and reliability. However, the MSV (0.585) was greater than the AVE for depression (0.566), confirming that the model has insufficient discriminant validity. The measurement of model fit is as follows: CMIN/df = 3.237; RMSEA = 0.141; SRMR = 0.023, TLI = 0.901, and CFI = 0.983. The SRMR and CFI values satisfied the threshold, otherwise the CMIN/df, RMSEA, and TLI did not satisfy but were close to the threshold.
Fig. 1

Structural equation model of (A) 2-factor and (B) 1-factor model. Arrows from factors to items represent factor loading. Arrow between factors represent correlation.

After recognizing the result of exploratory factor analysis, we then constructed a 1-factor model (Fig. 1B) and tested whether it better explains the structure of the PHQ-4. The AVE was 0.459, which is under threshold, and the CR was 0.796. The following values were obtained for model fit: CMIN/df, 6.353; RMSEA, 0.219; SRMR, 0.054; TLI, 0.762; and CFI, 0.921. As observed, all values were unfavorable compared to the 2-factor model, and only the SRMR satisfied the threshold.

DISCUSSION

This study has several main findings. First, the Korean version of the PHQ-4 was found to be a valid and reliable instrument for screening depression and anxiety. Second, this is the first study that standardized the PHQ-4 in the psychiatric unit. Unlike studies on the general population or a primary care clinical sample, the 2-factor structure of the PHQ-4 was incomplete. The construct validity of the PHQ-4 showed significance supported by high Pearson correlation coefficients with existing depression/anxiety scales. In the analysis of the correlations between the PHQ-4 and other existing depression/anxiety scales, the PHQ-4 total score was observed to have a higher correlation than the PHQ-4 depression/anxiety subscores. The high comorbidity of depressive and anxiety disorders [36] may have an effect on this finding. With both depression/anxiety subscores (synonymous with PHQ-2 and GAD-2 each) having cut points of 3 or greater, as suggested by previous studies [7,10], 50 (44.2%) patients have both depression and anxiety, 22 (19.5%) have only depression, 12 (10.6%) have anxiety only, and 29 (25.7%) have neither depression nor anxiety. Among the patients with depression, 69.4% have comorbid anxiety, and among the patients with anxiety, 80.6% have comorbid depression. The comorbidity of depression and anxiety in this study was higher than the previous PHQ-4 study conducted on primary-care clinical sample [12]. Using confirmatory factor analysis, the correlation of the depression and the anxiety factors was high at 0.768, and the discriminant validity was insufficient. Several model fit values also suggest that the two-factor model may not be perfectly suitable. The incompleteness of the 2-factor structure found in this study was inconsistent with previous PHQ-4 studies, and this may be attributable to the sample characteristics. In this study, subjects were recruited from the psychiatric department, whereas other studies recruited from the general population or primary-care sites. The mean score of the PHQ-4 in this study was 6.52 (SD 3.45), and it is significantly higher than in the German general population (1.76, SD 2.06) [18], in the Columbian general population (1.27, SD 2.01) [37], in undergraduate students from the United States (2.98) [38], and in a primary-care site sample from the United States (2.5, SD 2.8) [12]. The high symptom burden and aforementioned high comorbidity of depression and anxiety would have blurred the distinction between the two factors. The reliability test demonstrated that the Korean version of the PHQ-4 is a reliable instrument. The internal consistency of the Korean version of the PHQ-4 was found to have a sufficient value of 0.792. The value was slightly lower than previous PHQ-4 standardization studies ranging from 0.81 to 0.85 [12,18,37,38], but the value was close to them. This study is the first that reports the test-retest reliability of the PHQ-4. Although the treatment between 2 weeks of test-retest interval would have negatively affected it, the intraclass correlation coefficient representing test-retest reliability showed an excellent value of 0.827. The usage of standard diagnostic interview and the demonstration of test-retest reliability are the strengths of the present study. However, the biased study sample is a limitation. Löwe et al. [18] recommended considering PHQ-4 scores of 6 (percentile 95.7%) or greater as “yellow flags”, but 54.9% in this study sample correspond to “yellow flags”. Since the recruiting site was the psychiatric department of the university hospital, more severe patients would have visited compared to a primary-care clinic. Other diagnoses except for major depressive disorder (57.6%), panic disorder (27.6%), and adjustment disorder (9.0%), were all below 5%. In conclusion, the Korean version of the PHQ-4 showed sufficient internal consistency, test-retest reliability, and construct validity. However, its 2-factor structure was incomplete in a psychiatric clinic setting characterized by high psychiatric prevalence and comorbidity. Therefore, we suggest that it should be used as brief screening measure for general psychiatric distress that warrants further detailed assessment, but not to separately assess the severity of depression and anxiety symptoms in a psychiatric clinic setting. To investigate the normative data and to confirm the factor structure of the Korean version of the PHQ-4 in settings with relatively low prevalence and comorbidity, future studies should be done in the general population.
  26 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

2.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

3.  Prevalence, recognition and management of depression in primary care in Germany: the Depression 2000 study.

Authors:  Hans-Ulrich Wittchen; David Pittrow
Journal:  Hum Psychopharmacol       Date:  2002-06       Impact factor: 1.672

4.  Effects of a clinical-practice guideline and practice-based education on detection and outcome of depression in primary care: Hampshire Depression Project randomised controlled trial.

Authors:  C Thompson; A L Kinmonth; L Stevens; R C Peveler; A Stevens; K J Ostler; R M Pickering; N G Baker; A Henson; J Preece; D Cooper; M J Campbell
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

5.  Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection.

Authors:  Kurt Kroenke; Robert L Spitzer; Janet B W Williams; Patrick O Monahan; Bernd Löwe
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

6.  Prevalence of major depressive disorder in the general population of South Korea.

Authors:  Maurice M Ohayon; Seung-Chul Hong
Journal:  J Psychiatr Res       Date:  2006-02       Impact factor: 4.791

7.  Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.

Authors:  J Alonso; M C Angermeyer; S Bernert; R Bruffaerts; T S Brugha; H Bryson; G de Girolamo; R Graaf; K Demyttenaere; I Gasquet; J M Haro; S J Katz; R C Kessler; V Kovess; J P Lépine; J Ormel; G Polidori; L J Russo; G Vilagut; J Almansa; S Arbabzadeh-Bouchez; J Autonell; M Bernal; M A Buist-Bouwman; M Codony; A Domingo-Salvany; M Ferrer; S S Joo; M Martínez-Alonso; H Matschinger; F Mazzi; Z Morgan; P Morosini; C Palacín; B Romera; N Taub; W A M Vollebergh
Journal:  Acta Psychiatr Scand Suppl       Date:  2004

8.  Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study.

Authors:  Changsu Han; Sangmee Ahn Jo; Ji-Hyun Kwak; Chi-Un Pae; David Steffens; Inho Jo; Moon Ho Park
Journal:  Compr Psychiatry       Date:  2007-10-24       Impact factor: 3.735

9.  Projections of global mortality and burden of disease from 2002 to 2030.

Authors:  Colin D Mathers; Dejan Loncar
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

View more
  5 in total

1.  The factor structure and measurement invariance of the PHQ-4 and the prevalence of depression and anxiety in a Southeast Asian context amid the COVID-19 pandemic.

Authors:  Norman B Mendoza; Cherry E Frondozo; John Ian Wilzon T Dizon; Jet U Buenconsejo
Journal:  Curr Psychol       Date:  2022-03-01

2.  Scrambler Therapy for Chronic Pain after Burns and Its Effect on the Cerebral Pain Network: A Prospective, Double-Blinded, Randomized Controlled Trial.

Authors:  Seung Yeol Lee; Chang-Hyun Park; Yoon Soo Cho; Laurie Kim; Ji Won Yoo; So Young Joo; Cheong Hoon Seo
Journal:  J Clin Med       Date:  2022-07-22       Impact factor: 4.964

3.  Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study.

Authors:  Sungwon Roh; Kang Soo Lee; Songhwa Choi; Jae-Min Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-08-31       Impact factor: 3.731

4.  The Prevalence of Depression, Anxiety and Associated Factors among the General Public during COVID-19 Pandemic: a Cross-sectional Study in Korea.

Authors:  Dong Min Kim; Young Rong Bang; Joon Hee Kim; Jae Hong Park
Journal:  J Korean Med Sci       Date:  2021-07-26       Impact factor: 2.153

5.  Family Empowerment (FAME): A feasibility trial of preventive multifamily groups for asylum seeker families in the Netherlands.

Authors:  Carlijn M van Es; Paul A Boelen; Marieke Zwaanswijk; Hans Te Brake; Trudy Mooren
Journal:  J Marital Fam Ther       Date:  2021-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.